Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2010-12-21
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, carboplatin, and
paclitaxel and work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.
Giving hydroxychloroquine together with carboplatin, paclitaxel and bevacizumab may kill more
tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of
hydroxychloroquine when given together with carboplatin, paclitaxel, and bevacizumab and to
see how well they work in treating patients with recurrent advanced non-small cell lung
cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey